Metrum Research Group (United States)

Recent papers from Metrum Research Group (United States)

1. Balancing Analgesic Effects and Abuse Liability in Older Adults: A Randomized, Placebo-Controlled Trial of Oral and Vaporized Δ9-Tetrahydrocannabinol2026
2. Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post‐Transplant CyclophosphamideThe Journal of Clinical Pharmacology · 2026
3. Expanding Quantitative Medicines' Reach: Systems and Methods to Enhance R&D Productivity and Decision‐Making in the Agentic‐EraClinical and Translational Science · 2026
4. Epcoritamab Step‐Up Dosing Regimen Selection and Optimization Using Repeated Time‐to‐Event Modeling for Cytokine Release Syndrome Risk MitigationClinical Pharmacology & Therapeutics · 2026
5. Development of an Agent‐Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene DezaparvovecCPT Pharmacometrics & Systems Pharmacology · 2026
6. Abstract 6846: Using physiologically-based pharmacokinetics-quantitative systems pharmacology model to optimize peptide-drug conjugates design.Cancer Research · 2026
7. Exposure-Response: Tacrolimus Dosing and Acute Graft Versus Host Disease in Allogeneic Hematopoietic Cell Transplant RecipientsTransplantation and Cellular Therapy · 2026
8. Some Common Dose–Exposure–Response Estimands and Conditions for Their Causal IdentifiabilityCPT Pharmacometrics & Systems Pharmacology · 2026
9. A Population Pharmacokinetic and Exposure–Response Analysis for Baricitinib in Pediatric Patients with Atopic DermatitisClinical Pharmacokinetics · 2025
10. A Population Pharmacokinetic and Exposure–Response Analysis for Baricitinib in Pediatric Patients with Atopic DermatitisClinical Pharmacokinetics · 2025
11. Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotinJournal of Pharmacokinetics and Pharmacodynamics · 2025
12. Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell LymphomaThe Journal of Clinical Pharmacology · 2025
13. Physiologically-based pharmacokinetic model for predicting drug-drug interactions perpetrated by posaconazole in healthy subjects with normal weight and obesity: Concomitant use and washoutJournal of Pharmacokinetics and Pharmacodynamics · 2025
14. QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategynpj Systems Biology and Applications · 2025
15. Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitusBritish Journal of Clinical Pharmacology · 2025
16. Crowdsourcing Proposal Supporting Patient Engagement in Parkinson's Disease: A Digital Research Environment (DRE)‐Enabled, Patient Swarm Approach to Develop QSP ModelsThe Journal of Clinical Pharmacology · 2025
17. Exposure–Response Relationships in Patients with Non‐Small‐Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3‐DXd)Clinical Pharmacology & Therapeutics · 2025
18. AI‐Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI PreconferenceClinical and Translational Science · 2025
19. Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial CostClinical Pharmacology & Therapeutics · 2025
20. Population Pharmacokinetic/Pharmacodynamic and Exposure–Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary AngioedemaCPT Pharmacometrics & Systems Pharmacology · 2025